CEER Assay for PI3K Pathway Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting clinical sensitivity to PI3K inhibitors in cancer treatment are inadequate, as the presence of PI3K somatic mutations does not reliably predict therapeutic response, and there is a need for predictive biomarker assays to determine clinical sensitivity to PI3K inhibitors and combination therapies.
Innovation Solution
A method for measuring the level of dimerization of receptor tyrosine kinases (RTKs) and PI3K pathway components in cancer patients, using a combination of capture and detection antibodies to generate an amplified signal, allowing for the selection of appropriate anticancer drugs based on reference profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If PI3K somatic mutations are used as predictive biomarkers, then the assay is simple to perform, but the prediction accuracy of therapeutic response is insufficient
Solution Approach 1:
The patent combines multiple detection approaches (dimerization assays, phosphorylation status detection, protein complex formation analysis) into a comprehensive profiling system. This merging of multiple biomarker assessments resolves the contradiction by maintaining operational feasibility while significantly improving prediction accuracy through multi-parameter evaluation rather than relying on single mutation status.
Solution Approach 2:
The assay system is designed to detect multiple aspects of RTK and PI3K pathway activation simultaneously - dimerization, phosphorylation, and protein interactions. This multi-functional approach allows a single comprehensive assay to replace multiple separate tests, improving predictive accuracy while maintaining ease of operation through integrated testing.
2Measurement precision
If comprehensive pathway profiling is implemented, then prediction accuracy improves, but assay complexity increases
Solution Approach 1:
The comprehensive profiling assay is divided into distinct modular detection steps: dimerization detection, phosphorylation status detection, and protein complex formation analysis. Each module can be independently optimized and performed, reducing overall complexity while maintaining comprehensive coverage of pathway activation states for improved prediction accuracy.
Solution Approach 2:
The patent employs intermediary molecules and detection reagents that facilitate simultaneous measurement of multiple pathway parameters. These intermediaries enable the complex profiling to be achieved through a coordinated sequence of standardized biochemical reactions, making the comprehensive assay more manageable and less complex than direct simultaneous measurement would require.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the prediction of clinical benefit from PI3K inhibitor or combination therapy by quantitatively assessing PI3K pathway activation, aiding in cancer diagnosis, prognosis, and treatment design, and identifying patients who may benefit from specific therapies.
Implementation Method 1
the facilitating moiety generates an oxidizing agent which channels to and reacts with the first member of the signal amplification pair
Data Source
Figure 1A~1C
Figure 2
Figure 3
AI summary
The present invention provides methods for detecting, measuring and quantitating the activation states of components of the PI3K signaling pathway in cells such as tumor cells and selecting an anticancer therapy therewith. The methods involve a collaborative enzyme enhanced reactive-immunoassay (CEER) in which first activation state-independent antibodies specific for one member of a dimerised receptor tyrosine kinase (RTK) pair or a PI3K p110 subunit are labeled with a facilitating moiety (e.g. glucose oxidase) and second activation state-independent or dependent antibodies specific for the other member of the RTK pair or PI3K p85 or PI3K p110 subunit labeled with a signal amplification moiety (e.g. HRP).